These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Integrase inhibitors in the treatment of HIV-1 infection. Powderly WG J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268 [TBL] [Abstract][Full Text] [Related]
26. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234 [TBL] [Abstract][Full Text] [Related]
27. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance. Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984 [TBL] [Abstract][Full Text] [Related]
28. 5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. Peese KM; Allard CW; Connolly T; Johnson BL; Li C; Patel M; Sorensen ME; Walker MA; Meanwell NA; McAuliffe B; Minassian B; Krystal M; Parker DD; Lewis HA; Kish K; Zhang P; Nolte RT; Simmermacher J; Jenkins S; Cianci C; Naidu BN J Med Chem; 2019 Feb; 62(3):1348-1361. PubMed ID: 30609350 [TBL] [Abstract][Full Text] [Related]
29. Biochemical screening assays to identify HIV-1 integrase inhibitors. Clynhens M; Smets A; Vereycken I; Van Loock M; Clayton R; Meersseman G; Goethals O Methods Mol Biol; 2013; 1030():25-36. PubMed ID: 23821258 [TBL] [Abstract][Full Text] [Related]
30. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269 [TBL] [Abstract][Full Text] [Related]
31. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors. Ravichandran V; Shalini S; Sundram K; Sokkalingam AD Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187 [TBL] [Abstract][Full Text] [Related]
32. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Geretti AM; Armenia D; Ceccherini-Silberstein F Curr Opin Infect Dis; 2012 Dec; 25(6):677-86. PubMed ID: 23086187 [TBL] [Abstract][Full Text] [Related]
33. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Lataillade M; Chiarella J; Kozal MJ Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566 [TBL] [Abstract][Full Text] [Related]
34. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908 [TBL] [Abstract][Full Text] [Related]
35. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674 [TBL] [Abstract][Full Text] [Related]
36. HIV integrase inhibitors as therapeutic agents in AIDS. Nair V; Chi G Rev Med Virol; 2007; 17(4):277-95. PubMed ID: 17503547 [TBL] [Abstract][Full Text] [Related]
37. In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer. Voet AR; Maeyer MD; Debyser Z; Christ F Future Med Chem; 2009 Oct; 1(7):1259-74. PubMed ID: 21426102 [TBL] [Abstract][Full Text] [Related]
38. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342 [TBL] [Abstract][Full Text] [Related]
39. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Hazuda DJ Braz J Infect Dis; 2010; 14(5):513-8. PubMed ID: 21221483 [TBL] [Abstract][Full Text] [Related]
40. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]